Please provide your email address to receive an email when new articles are posted on . IVUS may improve care of patients undergoing peripheral revascularization. More data are needed to document ...

Data are early, retrospective, and unlikely to influence guidelines, but interest among operators is growing, says Sameh ...

Please provide your email address to receive an email when new articles are posted on . In a cohort of patients with renal impairment who underwent peripheral revascularization, rivaroxaban reduced ...

Compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors were associated with lower risks of cardiac death and composite renal outcomes without ...

Things seem to be looking up for the field of endovascular revascularization for symptomatic peripheral artery disease (PAD), researchers suggested. Paclitaxel-coated devices were safe for patients ...

Treatment with rivaroxaban plus aspirin significantly reduced the risk of major adverse limb and cardiovascular events in the VOYAGER PAD study. A supplemental New Drug Application (sNDA) for ...

Compared with white patients, Black patients with PAD who undergo peripheral revascularization have much more advanced disease at the time of their procedures and are less likely to receive necessary ...

Lower-extremity peripheral artery disease affects more than 200 million people worldwide. Patients who undergo peripheral revascularization are at high risk for subsequent complications; their risk ...

New clinical results highlight the need for inclusive approaches and comprehensive examinations of treatment options for peripheral artery disease (PAD), including endovascular therapy and ...

"Our findings highlight the clinical importance of focusing on total disease burden, rather than first events, and the need for long-term preventive strategies in high-risk patients."—Michael Szarek, ...

Among older veterans with type 2 diabetes (T2D), the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors as an add-on therapy is associated with a higher risk for peripheral artery disease ...